News

December 17, 2018

Fast Track Designation Granted for Macular Telangiectasia Type 2 (MacTel)

June 17, 2017

Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.

April 29, 2016

Neurotech Announces Renewed Focus on NT-501 (CNTF) Encapsulated Cell Therapy Clinical Programs.

November 2, 2013

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implant

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases by Kauper et al.

August 6, 2013

James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals.

July 24, 2012

NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)